185 related articles for article (PubMed ID: 32498019)
1. Auto In Silico Ligand Directing Evolution to Facilitate the Rapid and Efficient Discovery of Drug Lead.
Wu F; Zhuo L; Wang F; Huang W; Hao G; Yang G
iScience; 2020 Jun; 23(6):101179. PubMed ID: 32498019
[TBL] [Abstract][Full Text] [Related]
2. Protocol for hit-to-lead optimization of compounds by auto
Mei L; Wu F; Hao G; Yang G
STAR Protoc; 2021 Mar; 2(1):100312. PubMed ID: 33554146
[TBL] [Abstract][Full Text] [Related]
3. ACFIS: a web server for fragment-based drug discovery.
Hao GF; Jiang W; Ye YN; Wu FX; Zhu XL; Guo FB; Yang GF
Nucleic Acids Res; 2016 Jul; 44(W1):W550-6. PubMed ID: 27150808
[TBL] [Abstract][Full Text] [Related]
4. ACFIS 2.0: an improved web-server for fragment-based drug discovery via a dynamic screening strategy.
Shi XX; Wang ZZ; Wang F; Hao GF; Yang GF
Nucleic Acids Res; 2023 Jul; 51(W1):W25-W32. PubMed ID: 37158247
[TBL] [Abstract][Full Text] [Related]
5. ACID: a free tool for drug repurposing using consensus inverse docking strategy.
Wang F; Wu FX; Li CZ; Jia CY; Su SW; Hao GF; Yang GF
J Cheminform; 2019 Nov; 11(1):73. PubMed ID: 33430982
[TBL] [Abstract][Full Text] [Related]
6. Chemistry-driven Hit-to-lead Optimization Guided by Structure-based Approaches.
Hoffer L; Muller C; Roche P; Morelli X
Mol Inform; 2018 Sep; 37(9-10):e1800059. PubMed ID: 30051601
[TBL] [Abstract][Full Text] [Related]
7. In silico tools used for compound selection during target-based drug discovery and development.
Caldwell GW
Expert Opin Drug Discov; 2015; 10(8):901-23. PubMed ID: 25952011
[TBL] [Abstract][Full Text] [Related]
8. Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors.
Yuan H; Liu Q; Zhang L; Hu S; Chen T; Li H; Chen Y; Xu Y; Lu T
Eur J Med Chem; 2018 Jan; 143():491-502. PubMed ID: 29202410
[TBL] [Abstract][Full Text] [Related]
9. PADFrag: A Database Built for the Exploration of Bioactive Fragment Space for Drug Discovery.
Yang JF; Wang F; Jiang W; Zhou GY; Li CZ; Zhu XL; Hao GF; Yang GF
J Chem Inf Model; 2018 Sep; 58(9):1725-1730. PubMed ID: 30134653
[TBL] [Abstract][Full Text] [Related]
10. AIMMS suite: a web server dedicated for prediction of drug resistance on protein mutation.
Wu FX; Wang F; Yang JF; Jiang W; Wang MY; Jia CY; Hao GF; Yang GF
Brief Bioinform; 2020 Jan; 21(1):318-328. PubMed ID: 30496338
[TBL] [Abstract][Full Text] [Related]
11. Integrated Strategy for Lead Optimization Based on Fragment Growing: The Diversity-Oriented-Target-Focused-Synthesis Approach.
Hoffer L; Voitovich YV; Raux B; Carrasco K; Muller C; Fedorov AY; Derviaux C; Amouric A; Betzi S; Horvath D; Varnek A; Collette Y; Combes S; Roche P; Morelli X
J Med Chem; 2018 Jul; 61(13):5719-5732. PubMed ID: 29883107
[TBL] [Abstract][Full Text] [Related]
12. Reaction-Based Enumeration, Active Learning, and Free Energy Calculations To Rapidly Explore Synthetically Tractable Chemical Space and Optimize Potency of Cyclin-Dependent Kinase 2 Inhibitors.
Konze KD; Bos PH; Dahlgren MK; Leswing K; Tubert-Brohman I; Bortolato A; Robbason B; Abel R; Bhat S
J Chem Inf Model; 2019 Sep; 59(9):3782-3793. PubMed ID: 31404495
[TBL] [Abstract][Full Text] [Related]
13. Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach.
Kapetanovic IM
Chem Biol Interact; 2008 Jan; 171(2):165-76. PubMed ID: 17229415
[TBL] [Abstract][Full Text] [Related]
14. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective.
Zhao H
Drug Discov Today; 2007 Feb; 12(3-4):149-55. PubMed ID: 17275735
[TBL] [Abstract][Full Text] [Related]
15. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
[TBL] [Abstract][Full Text] [Related]
16. Novel approach of fragment-based lead discovery applied to renin inhibitors.
Tawada M; Suzuki S; Imaeda Y; Oki H; Snell G; Behnke CA; Kondo M; Tarui N; Tanaka T; Kuroita T; Tomimoto M
Bioorg Med Chem; 2016 Nov; 24(22):6066-6074. PubMed ID: 27720325
[TBL] [Abstract][Full Text] [Related]
17. The In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization.
Bruno A; Costantino G; Sartori L; Radi M
Curr Med Chem; 2019; 26(21):3838-3873. PubMed ID: 29110597
[TBL] [Abstract][Full Text] [Related]
18. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
19. Computational Methods Used in Hit-to-Lead and Lead Optimization Stages of Structure-Based Drug Discovery.
Heifetz A; Southey M; Morao I; Townsend-Nicholson A; Bodkin MJ
Methods Mol Biol; 2018; 1705():375-394. PubMed ID: 29188574
[TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
